Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
6-1-2021

Placental pathology in an unsuspected case of mucolipidosis
type II with secondary hyperparathyroidism in a premature infant
Parith Wongkittichote
Washington University School of Medicine in St. Louis

Garland Michael Upchurch
Washington University School of Medicine in St. Louis

Louis P Dehner
Washington University School of Medicine in St. Louis

Timothy Wood
Greenwood Genetic Center

Jorge L Granadillo
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Wongkittichote, Parith; Upchurch, Garland Michael; Dehner, Louis P; Wood, Timothy; and Granadillo, Jorge
L, ,"Placental pathology in an unsuspected case of mucolipidosis type II with secondary
hyperparathyroidism in a premature infant." Molecular Genetics and Metabolism Reports. 27,. . (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10250

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Molecular Genetics and Metabolism Reports 27 (2021) 100747

Contents lists available at ScienceDirect

Molecular Genetics and Metabolism Reports
journal homepage: www.elsevier.com/locate/ymgmr

Case Report

Placental pathology in an unsuspected case of mucolipidosis type II with
secondary hyperparathyroidism in a premature infant
Parith Wongkittichote a, Garland Michael Upchurch b, Louis P. Dehner b, Timothy Wood c,
Jorge L. Granadillo a, *
a

Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States of America
Department of Pathology and Immunology (Lauren V. Ackerman Laboratory of Surgical Pathology), Washington University School of Medicine, St Louis, MO, United
States of America
c
Greenwood Genetic Center, Greenwood, SC, United States of America
b

A R T I C L E I N F O

A B S T R A C T

Keywords:
Mucolipidosis type II
GNPTAB-related disorders
Trophoblastic lipidosis

Mucolipidosis type II (MLII, MIM 252500) is a lysosomal storage disorders caused by defects in GNPTAB gene
which encodes alpha and beta subunits of N-acetylglucosamine (GlcNAc)-1-phosphotransferase. Neonatal pre
sentation includes coarse facial features, restricted postnatal growth, generalized hypotonia, gingival hyper
trophy and multiple skeletal anomalies. Here we present a case of a 26-week gestational age preterm infant with
MLII who did not exhibit the typical facial features at birth; however, the diagnosis was suggested from abnormal
placental pathology showing trophoblastic lipidosis and initial skeletal abnormalities from chest radiograph
revealing generalized diffuse severe bone demineralizing disease and multiple fractures. Biochemical testing
revealed elevation of plasma lysosomal enzymes. Homozygous pathogenic variant, designated c.3505_3504del,
was discovered from GNPTAB sequencing. Her course was complicated by respiratory distress, secondary hy
perparathyroidism, abdominal distention and feeding difficulties. Urine mucopolysaccharides analysis revealed
mild elevation of total and individual glycosaminoglycan species in a non-specific pattern. To our knowledge, our
case is the most premature example of mucolipidosis type II that has ever been reported to date. This report
highlights the importance of placental pathological studies in the diagnosis of lysosomal storage disorders.

1. Introduction
Mucolipidosis type II (MLII, also known as I-cell disease), along with
mucolipidosis type III alpha/beta (MLIIIα/β) and mucolipidosis type III
gamma (MLIIIγ), are lysosomal storage disorders caused by defects in Nacetylglucosamine (GlcNAc)-1-phosphotransferase [1,2]. GlcNAc-1phosphotransferase is a hexameric enzyme composed of 2 alpha, 2
beta and 2 gamma subunits [2,3]. GNPTAB encodes the alpha and beta
subunits, while GNPTG encodes the gamma subunit [4,5]. This enzyme
catalyzes the phosphorylation of mannose residues on glycan chains to
form mannose-6-phosphate, which is required for targeting lysosomal
enzymes to lysosomes [6]. The defect of GlcNAc-1-phosphotransferase
causes hypersecretion of lysosomal enzymes leading to the elevation
of multiple acid hydrolase activities in the serum and their deficiency in
the lysosomes. [7]. The subsequent accumulation of intracellular ma
terials results in cellular dysfunction and eventually tissue and organ

damage [8].
GNPTAB is located at chromosome 12q23.2 and contains 21 exons.
Pathogenic variants in GNPTAB cause MLII (MIM 252500) and MLIIIα/β
(МІM 252600) [2,9]. MLII is characterized by neonatal onset of coarse
facial features, restricted postnatal growth, generalized hypotonia,
gingival hypertrophy and multiple skeletal abnormalities including
thoracic deformity, clubfeet, long bone deformity, hip dislocation, and
cardiac valvular abnormalities [1,10–14]. MLIIIα/β is a later-onset form
which is typically diagnosed around three years of age and has slower
progression [1,10–14]. Those with MLIIIα/β typically live into early
adulthood, while most patients with MLII die in early childhood, usually
with respiratory compromise [15]. Genotype-phenotype correlation has
been established in MLII and MLIIIα/β. Variants that severely affect
enzyme function have been shown to be associated with more severe
phenotypes [1,16].
Previous studies have reported abnormal placental lipid
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accumulation in newborns with mucolipidoses and other lysosomal
storage diseases [17–19]. We present the case of a premature newborn
with MLII who at birth did not exhibit any of the typical dysmorphic
features including those of the facies. It was on the basis of the placental
examination and radiographic findings of the chest that the diagnosis of
I-cell disease was suspected and subsequently corroborated through
biochemical and genetic testing.

Lysosomal enzyme testing was performed by Lysosomal Diseases
Testing Laboratory, Thomas Jefferson University (Philadelphia, PA)
[20]. Urine mucopolysaccharidosis analysis and urinary oligosaccharide
analysis were performed by Greenwood Genetic Center (Greenwood,
SC) using mass spectrometry based methods [21–23]. Total glycosami
noglycans were measured using dye binding methods.
2.3. Gross and microscopic examination of the placenta

2. Materials and methods

Gross examination with prosection of the placenta was performed by
standard surgical pathology techniques. The weight of the placental disc
with trimmed fetal membranes was measured and compared to a stan
dard reference range of placental weights for reported fetal gestational
age at birth. Placental sections submitted for microscopic examination
were formalin fixed/paraffin embedded and cut slides were hematoxylin
and eosin stained using standard histology techniques and were exam
ined by light microscopy. An additional section of placenta was fixed in
glutaraldehyde for electron microscopy by standard techniques, per
formed using standard techniques at the Washington University School
of Medicine Department of Pathology and Immunology electron mi
croscopy facility.

2.1. Case report
The patient was a 3-day-old female who was admitted to the
neonatal intensive care unit due to prematurity at 26 weeks of gestation
to a 26-year-old G1 P0 mother whose pregnancy was complicated by
prolonged premature rupture of membranes, preterm labor, recurrent
urinary tract infections and renal calculi. Family history was otherwise
unremarkable. Prenatal ultrasound at 25 weeks of gestation was re
ported as normal. Her birth weight was 1000 g (90th percentile); birth
length was 36.5 cm (94th percentile) and head circumference was 23 cm
(44th percentile). APGAR scores were 6 and 9 at 1 and 5 minutes of life,
respectively. She was started on continuous positive airway pressure
(CPAP) due to prematurity and was later transitioned to non-invasive
positive pressure ventilation (NIPPV) due to desaturations. She was
begun on a course of ampicillin and gentamicin due to prolonged
rupture of membranes. Her physical examination was unremarkable
without coarse facial features; however, a chest radiograph revealed
generalized diffuse severe bone demineralization and multiple fractures,
which raised concern for hyperparathyroidism. Further evaluation
revealed mildly elevated ionized calcium (5.26 mg/dL, normal range
3.90–5.20 mg/dL), an elevated parathyroid hormone (PTH) level (471
pg/mL, normal range 14–72 pg/mL), mildly low 25-hydroxyvitamin D
(17 ng/mL, normal range 20–100 ng/mL), elevated magnesium (3.2
mg/dL, normal range 1.4–2.5 mg/dL), normal phosphorus (4.5 mg/dL,
normal range 4.0–9.0 mg/dL) and elevated alkaline phosphatase (832
units/L, normal range 110–320 mg/dL). Maternal calcium, magnesium,
phosphorus, PTH and 25-hydroxyvitamin D were within the normal
range. PTH in subsequent studies of the proband showed improvement
to suggest secondary hyperparathyroidism. Vitamin D was initiated with
subsequent decrease in PTH level and normalization occurred at 8 weeks
of age; however, alkaline phosphatase has remained elevated. She
developed significant abdominal distention which improved with
decrease feeding volume. Oral feeds were intiated at 14 weeks of life;
however she struggled to achieve caloric goal. Gastrostomy tube was
placed prior to discharge. In terms of respiratory support, she was later
transitioned from NIPPV to nasal cannula; however, she developed
desaturation on room air. She was then discharged at 16 weeks of life
with low-flow nasal cannula. She failed auditory brainstem response
(ABR) test. Repeat audiologic study revealed mild-to-moderate bilateral
conductive hearing loss.

3. Results
3.1. Placental pathology
Gross examination showed a 12.5 × 12.0 × 2.7 cm singleton placenta
with an attached segment of unremarkable trivascular umbilical cord
inserting paracentrically 4.2 cm from the placental disc margin.
Attached membranes were opaque with eccentric rupture 2.5 cm from
the nearest placental disc margin. The fetal surface was pink in color
with gross sub-amniotic hemorrhage. The maternal surface was dis
rupted. Trimmed weight of the placenta was 183.6 g which was small for
pre-term female neonates born at 26 weeks gestational age and corre
sponding to less than the 10th percentile for gestational age. Sections of
the placental disc showed no additional gross findings.
Microscopic examination showed a trivascular umbilical cord and
fetal membranes showed no histopathologic abnormality. The chorionic
villi with appropriate maturation for gestational age revealed fine
vacuolization of syncytiotrophoblasts and stromal expansion by multi
vacuolated Hofbauer cells (fetal macrophages) (Fig. 1). Extensive cyto
plasmic vacuolization of Hofbauer cells with some electron dense
material within the vacuoles was identified ultrastructurally (Fig. 2).
These vacuoles were most consistent with lysozymes containing lipid
suggestive of mucolipidoses, namely MLII [17] or mucolipidosis type IV
[18].
3.2. Biochemical and molecular analysis
Lysosomal enzyme testing in leukocytes was normal; however,
plasma lysosomal enzymes including β-galactosidase, β-mannosidase,
α-L-fucosidase, α-mannosidase and α-glucosaminidase activities were
substantially elevated; this finding is consistent with MLII or MLIIIα/β.
Targeted sequencing revealed that the patient was homozygous for a
pathogenic variant in GNPTAB, denoted NM_024312.5: c.3505_3504del
(p.Leu1168Glnfs*5). This variant has been previously reported to be
causative for MLII. Both parents were found to be heterozygotes.
Urine mucopolysaccharides analysis revealed a non-specific pattern
(Table 1). At 2 days of life, all individual GAGs, including chondroitin
sulfate (CS), heparan sulfate (HS), dermatan sulfate (DS) and keratan
sulfates (KS) were elevated, with normal total GAGs. Repeat study at 2
months of age consistently showed elevation of CS, HS and KS. The total
GAGs were also elevated, while DS normalized. A similar pattern was
noted in two additional samples taken at 2 months of age.
Urinary oligosaccharide analysis demonstrated significant elevations
(3.6–11.3 times) of a sialylated oligosaccharide marker

2.2. Molecular and biochemical analysis
Genetic testing for GNPTAB was performed on the index patient and
her parents by Prevention Genetics (Marshfield, WI). Genomic DNA was
extracted from buccal swabs of the proband as well as the parents. DNA
corresponding to these regions was captured using an optimized set of
DNA hybridization probes. Captured DNA was sequenced using Illumi
na’s Reversible Dye Terminator (RDT) platform (Illumina, San Diego,
CA, USA). Regions with insufficient coverage by next-generation
sequencing (NGS) were covered by Sanger sequencing. Copy number
variants (CNVs) were detected from NGS data utilizing a CNV calling
algorithm that compares mean read depth and distribution for each
target in the test sample against multiple matched controls. The depth of
coverage was more than 20× for all coding exons of GNPTAB, GNPTC
and NAPGA, plus approximately 10 bases flanking of noncoding DNA.
2
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Fig. 2. Electron micrograph of placental villus. Trophoblastic lipidosis was
shown, consistent with lysosomal lipid inclusions.

4. Discussion
The placental examination provides the opportunity to identify both
maternal and fetal findings which correlate a variety of pregnancy
associated complications from maternal vascular malperfusion with in
trauterine growth restriction to fetal infections of various types in the
presence of fetal hydrops. Our case illustrates that clinically pertinent
findings (and subsequent diagnoses made) are by no means restricted to
these narrow diagnostic categories and can include a number of
biochemical disorders – namely inborn errors of lipid metabolism. It has
been appreciated for some time that electron microscopy is especially
useful in a variety of inherited lipid storage disorders with the lysosomal
accumulation of metabolic material in Hofbauer cells as it does else
where in fetal macrophages in the liver, spleen and lymph nodes [24].
Here we present a case where the findings of placental lipidosis raised
concern for an inborn error of lipid metabolism, which was further
confirmed by electron microscopic studies showing lysosomal lipid in
clusions as well as biochemical and genetic evidence of MLII. While MLII
is a rare genetic disease, even rarer are reports in the literature of di
agnoses being made based on placental findings [17,18,25].
A diagnosis of MLII is usually suspected based on clinical charac
teristics include early signs of dysmorphic features and abnormal skel
etal findings which may be present at birth to early infancy [10].
However, our case demonstrated that coarse facial features can be mild
or even absent in preterm newborns with MLII, but may develop later.
Skeletal findings, in combination with abnormal placental pathology,
can lead to the early recognition of MLII.
Spontaneous abortion and stillbirth have been reported among cases
with MLII [26,27]. In a cohort of individuals diagnosed with MLII,
Cathey SS et al. reported that two out of 14 had preterm deliveries [10].
Aborted fetuses were found to have abnormal placental pathology with
extensive cytoplasmic vacuolization of chorionic villi [27]. MLII might
increase the risk of stillbirth and preterm labor, partially due to

Fig. 1. Hematoxylin and Eosin section showing trophoblastic lipidosis. Foamy
vacuolization surrounding the periphery of the villus was noted, corresponding
to lysosomal lipid inclusions.

(Neu5Ac1Hex3HexNAc2) in all four urine samples. Other markers
(Hex1HexNAc1, Hex3HexNAc1, Hex3HexNAc2) were elevated in most
samples but to a lesser degree (1–3.3 times).
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Table 1
Urine mucopolysaccharides and oligosaccharides profiles in the proband. Red text indicates abnormal levels.
Chondroitin Sulfate
Dermatan Sulfate
Heparan Sulfate
Keratan Sulfate
Total GAGs
Neu5Ac1Hex3HexNAc2
Hex1HexNAc1
Hex3HexNAc1
Hex3HexNAc2

Normal range

Unit

D2

D55

D61

D68

0–36.81
0–18.47
0–5.28
0–18.8
0–53
0.08–0.72
12.0–60.3
7.4–33.6
1.6–4.2

g/mol creatinine
g/mol creatinine
g/mol creatinine
ug/mg creatinine
mg/mmol creatinine
Relative response
Relative response
Relative response
Relative response

79.89
21.55
19.10
23.64
33.33
7.4
106.4
54.2
13.7

61.35
12.83
8.14
27.49
68.35
8.1
104.4
39.2
8.4

64.52
14.32
6.66
30.87
90.15
2.6
60.0
26.6
5.5

57.16
12.66
11.52
39.14
66.39
3.8
68.5
35.3
6.6

placental injury from accumulation of storage material.
Our patient also had transient secondary hyperparathyroidism,
which has been previously reported in association with MLII [28–31].
The initially elevated PTH later normalized; however, alkaline phos
phatase has remained elevated, similar to previously reported examples
[29,30]. The cause of this endocrine abnormality is currently unclear.
Sathasivam, et al, proposed that abnormal placental structure and
function may lead to impaired placental calcium transport and subse
quent secondary hyperparathyroidism and ricket-like bone changes
[31]. Alternatively, David-Vizcarra, et al, hypothesized that GlcNAc-1phosphotransferase deficiency causes defective targeting of one of the
components of PTH signal transduction, leading to tissue PTH hyper
sensitivity and PTH hypersecretion from disrupted biofeedback [30].
Abnormal elevation of GAGs has been reported in the settings of MLII
and MLIIIα/β patients [31]. One patient was reported to have elevation
of DS, HS and KS, while another patient was found to have only DS
elevation. Our patient showed elevated total and individual GAGs. This
pattern differs from previous studies with the elevation of CS, HS, and
KS. Additionally, abnormal urinary oligosaccharides have been reported
in MLII and MLIIIα/β patients [21]. Our patient showed persistent ele
vations of a sialylated oligosaccharide and to a lesser degree other nonsialyated oligosaccharides. The abnormal levels of GAGs and oligosac
charides in mucolipidoses are less significant than those in mucopoly
saccharidoses and glycoproteinoses, respectively; however, in
conjunction with other clinical features, mild nonspecific elevation of
both tests can support a diagnosis of MLII. Additionally our data show
these mild elevations persist over multiple samples and are present in
the first week of life.
We have described a premature infant who was diagnosed with MLII
on the basis of placental lipidosis, skeletal findings and subsequent ge
netic confirmation. To our knowledge, this patient is the most premature
patient with MLII to date that has been reported. Given the absence of
classical craniofacial features at the time of diagnosis, this report has
highlighted the importance of placental pathological examination in
cases of unsuspected disorders especially of an inherited metabolic
nature.
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